Four patients with progressive limb paralysis after recreationally inhaling N2O were admitted to the neuromuscular clinic. All of the patients were women, were aged 21-36 years, had abused N2O for between 1 and 5 months, and exhibited some degree of motor weakness in the lower extremities. Sensory examinations revealed paresthesia in three of the four patients. Patient 1 had no sensory deficit and described a tingling sensation, while Patient 3 reported burning pain. Two patients (Patients 2 and 3) had decreased positional and vibration senses, and a positive Romberg's sign. In addition to the neurological deficit, Patient 4 showed psychiatric symptoms such as irritability, agitation, reduced sleep, delusions of references (i.e., thinking that others were doubting her), and anxiety. (Fig. 1) . However, Patient 4, who initially had normal spine MRI findings, continued to inhale N2O gas, and follow-up MRI showed high T2-weighted signals in the posterior column ( Fig. 1I and J) .
For treatment, intramuscular vitamin B12 was administered to all patients. Patient 1 additionally received intravenous immunoglobulin therapy for 5 days to address the superimposed Guillain-Barré syndrome. Patient 4 received a direct oral anticoagulant (apixaban, 5 mg bid) due to pulmonary thromboembolisms.
Neuropathy induced by N2O has various clinical and neurophysiological manifestations.
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axonal neuropathy that progressed to motor-dominant polyneuropathy. N2O increases the homocysteine level, which increases the risk of thrombosis. 5 Patient 4 did not have any symptoms or signs of a pulmonary embolism, but this was detected incidentally in spinal MRI and represents a rare case of incidental pulmonary thromboembolism due to N2O abuse.
In conclusion, N2O abuse can cause various clinical and neurophysiological manifestations of myeloneuropathy along with psychiatric and medical sequelae. The difficulty of ascertaining the presence of N2O abuse and its various clinical features mean that clinicians should not exclude the possibility of N2O toxicity in the differential diagnosis when examining patients with ascending paralysis. 
